Associate Professor and head of the Laboratory of Clinical immunology and Allergy (LIM-60), Division of Clinical Immunology and Allergy, Department of Medicine, and Investigator of the Heart Institute/Fundação Zerbini, University of São Paulo School of Medicine. Investigator class 1B, CNPq (Brazilian National Research Council). Investigator of the INCT for Investigation in Immunology.MD degree, University of Brasília (1988) and PhD on Immunology, University of São Paulo (1994). Visiting researcher in Stanford University (USA, 1991), Harvard University (USA, 2002), Istituto Roche Milano Ricerche, Italy (1996) and Aix-Marseille Université/INSERM, France ( 2012, 2017). He has experience in translational research on cellular and molecular immunology and immunopathology of human disease, focussing on the following subjects:Chagas disease, chronic Chagas disease cardiomyopathy, vaccine discovery, HIV, COVID-19. Recent emphasis has been on the role of mitochondrial damage, inflammation and genetics, as well as novel treatments for Chagas disease, and identification of biomarkers and vaccine development for COVID-19. In February 2023 he had 180 publications in peer-reviewed, indexed journals. The publications had been cited 5325 times, with an h index of 43 (ISI/WoS). One patent on an HIV vaccine was granted by USPTO and EPO (US and European Community) and pending in INPI (Brazil). Awarded with the Roche (1994), Santista-Juventude (1998) e Jairo Ramos (2002) nationwide scientific awards. (Source: Lattes Curriculum)
| Articles published in Pesquisa FAPESP Magazine about the researcher: |
| The third wave |
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Chagas disease (CD), caused by the protozoan parasite Trypanosoma cruzi, is a neglected disease affecting around 6 million people, with no effective antiparasitic drugs or vaccines. About 30% of CD patients develop chronic Chagas disease cardiomyopathy (CCC), an inflammatory cardiomyopathy that occurs decades after the initial infection, while most infected patients (60%) remain asymptoma…
Chagas Disease, caused by the protozoan parasite Trypanosoma cruzi, affects 5-8 million people worldwide. Only a fraction of infected patients develop chronic cardiac or digestive disease. The factors underlying the differential susceptibility to developing either of the symptomatic forms of chronic Chagas Disease are incompletely understood. During the chronic phase of infection, 30% of …
Dr Christophe Chevillard's scientific visit is crucial for the collaborative scientific program, which so far has shown to be very productive. It allowed publication of 14 scientific papers, 5 in various steps of writing; 7 supported grant proposals (two currently submitted and awaiting review). We will perform additional analysis and processing of data obtained in FAPESP/ANR collaborat…
Chagas disease, caused by the protozoan Trypanosoma cruzi, affects 15 million people. About 30% of Chagas disease patients develop Chronic Chagas disease cardiomyopathy (CCC), an particularly lethal inflammatory cardiomyopathy that occurs decades after the initial infection, while most patients remain asymptomatic (ASY;60%). Clinical severity in Chagas disease is correlated with the occur…
(Only some records are available in English at this moment)
About 30% of Chagas disease patients develop chronic Chagas disease cardiomyopathy (CCC), an inflammatory cardiomyopathy that occurs decades after the initial infection, while most infected patients (60%) remain asymptomatic in the so-called indeterminate form (IF). Myocardial fibrosis, inflammation and mitochondrial dysfunction are involved in the arrhythmia substrate and triggering even…
About 30% of Chagas disease patients develop chronic Chagas disease cardiomyopathy (CCC), an inflammatory cardiomyopathy that occurs decades after the initial infection, while most infected patients (60%) remain asymptomatic in the so-called indeterminate form (IF). Myocardial fibrosis, inflammation and mitochondrial dysfunction are involved in the arrhythmia substrate and triggering even…
(Only some records are available in English at this moment)
Since the emergence of the "new coronavirus", that causes COVID-19 disease, health systems and economies around the world have been devastated by the spread of the virus, responsible for causing millions of deaths. Vaccines represent the most effective and safest method to control the COVID-19 pandemic. In order to accelerate the protection of individuals, some vaccines based on the Spike…
Chagas disease (CHD) is a highly debilitating disease and affects around 1.2 million people in Brazil. Chronic chagasic cardiopathy (CCC) is the most severe clinical disease manifestation and affects 30% of patients, while 60% remain in the indeterminate form. There are no biomarkers of classification of the clinical forms and prognostic of progression to CCC, and these are urgently neede…
Chronic Chagas disease affects 10 million people, one-third of which will develop life-threatening cardiac disease years after infection. One of the most challenging tasks for the control and treatment of chronic Chagas disease is the development of anti-Trypanosoma cruzi therapy effective at this phase, the one where most cases are diagnosed. Benznidazole, which together with Nifurtimox …
(Only some records are available in English at this moment)
The pandemic of coronavirus disease (COVID-19), caused by the SARS-CoV-2 virus, has affected millions of people worldwide since its beginning in 2019. Even with the current availability of different vaccines and new antivirals and immunomodulatory interventions, thousands of infection cases and deaths are still registered daily. Although most infected individuals present mild to moderate …
| 1 / 1 | Ongoing research grants |
| 22 / 15 | Completed research grants |
| 4 / 4 | Ongoing scholarships in Brazil |
| 33 / 15 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 0 | Completed scholarships abroad |
| 63 / 37 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID